We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





First True POC COVID-19 Antibody Tests Offer Convenience and Ease of Use

By LabMedica International staff writers
Posted on 16 Jun 2020
Two newly-launched rapid COVID-19 antibody tests are awaiting Emergency Use Authorization (EUA) approval from the US FDA and once authorized, would become the first true point-of-care (POC) tests designed for convenience and ease of use, allowing providers to triage their patients as efficiently as possible.

Vivera Pharmaceuticals, Inc. More...
(Newport Beach, CA, USA) has launched the POC ready rapid serology tests which are designed to serve where patients most critically require screening testing. One test is optimized for use in mass-screening settings, such as drive through testing centers, and the other test is more suitable for use in doctor's offices and health clinics. Following in the footsteps of its first EUA filing, Vivera is voluntarily taking part in the National Cancer Institute backed validation studies for its two new filings. Vivera plans to use its serology antibody tests to begin its forthcoming clinical trials in support of eventual medical device filings with the FDA as the company further expands its advanced diagnostics division.

"Vivera has undergone clinical trials with nursing homes and health clinics and we have made refinements we feel will best serve the doctors and nurses who will be the ones using the test," stated Dr. Stephen McColgan, Vivera Pharmaceuticals' Chief Medical Officer. "Eventually, as the FDA finds the right pathway, we hope to transition into supporting telemedicine providers and expanding the availability of screening testing."


Related Links:
Vivera Pharmaceuticals, Inc.


Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Online QC Software
Acusera 24•7
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Research team leader Professor Klaus Gerwert and study lead author Dr. Grischa Gerwert in a betaSENSE laboratory (Photo courtesy of Dennis Yenmez/Stadt Bochum)

Blood-Based Sensor Detects Early Signs of Alzheimer’s and Parkinson’s

Alzheimer’s disease and Parkinson’s disease are increasing as populations age, yet diagnosis remains largely symptom-driven and often occurs after irreversible brain damage has begun. Earlier detection,... Read more

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.